The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Share News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: essensys loss widens; Carclo demand strong

Tue, 18th Oct 2022 22:04

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

essensys PLC - London-based software and cloud services for flexible workspace industry - In year ended July 31, pretax loss widens to GBP11.1 million from GBP2.9 million a year prior. Revenue rises to GBP23.3 million from GBP22.0 million. Administrative expenses grows to GBP24.3 million from GBP16.5 million. Chief Executive Mark Furness says period was a year of "progress and resilience". "Momentum with strategic customers remains and underpins a significant pipeline of opportunities. The quality of our customer base has helped us to manage near-term headwinds such as delays to sales cycles and capital deployment, some portfolio rebalancing among our larger flexible workspace operators and the expected churn at the tail-end of our customer base," he adds.

----------

Carclo PLC - West Yorkshire-based plastic parts manufacturer - Says demand in first six months of its financial year, ending March 31 2023, has been "strong", resulting in sales marginally ahead of board expectations and ahead of the prior year. It adds: "The inflation and supply chain challenges experienced in the first half are expected to continue through the remainder of the financial year. Our initiatives to further enhance operational efficiency and to offset inflationary price increases are key focus areas for the second half. Increases in borrowing costs are expected in the second half driven by increases in both the level of debt and interest rates."

----------

Angle PLC - Surrey, England-based medical diagnostics company - Decides to close facilities in Toronto, Canada in an orderly wind down. Notes it retains its high-specification clinical laboratory facility in Plymouth Meeting, Pennsylvania, US, as its central hub for North American activities. Says decision is part of commitment to tightly control costs and focus on near-term commercialisation of Parsortix system for cancer liquid biopsy. Hopes to reduce costs by GBP2.6 million in 2023, rising to GBP4.0 million after.

----------

Aptamer Group PLC - York, England-based provider of custom services, diagnostics and therapeutics for biotechnology and pharmaceutical firms - Pretax loss in year to June narrows to GBP2.6 million versus GBP2.9 million loss in 15 months to June 30, 2021. Revenue multiplies to GBP4.0 million from GBP1.6 million. Administrative expenses rise to GBP4.4 million from GBP3.1 million. Chief Executive Arron Tolley says: "Aptamer has maintained a solid pace of progress over the past year, having seen success in both expanding current partnerships and winning new contracts. Commercial traction continues to increase in Europe, US and APAC regions." Sees strong revenue growth in current financial year.

----------

Open Orphan PLC - London-based research organisation testing infectious and respiratory disease products - Appoints Stephen Pinkerton as chief financial officer, to replace Leo Toole who will step down at end of 2022. Pinkerton is chartered accountant with over 25 years of experience in senior financial roles and has served as Commercial Financial Director of hVIVO since July 2017. Also notes Cathal Friel is reverting to Non-Executive Chair after Yamin Khan appointment of chief executive officer.

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
17 Jan 2020 10:51

Open Orphan Takeover Of hVIVO Now Wholly Unconditional

Open Orphan Takeover Of hVIVO Now Wholly Unconditional

Read more
16 Jan 2020 18:15

Open Orphan Readmitted To AIM Following Reverse Takeover Of hVIVO

Open Orphan Readmitted To AIM Following Reverse Takeover Of hVIVO

Read more
14 Jan 2020 16:10

Open Orphan To Mount Compulsory Buyout To Get hVIVO Deal Over Line

Open Orphan To Mount Compulsory Buyout To Get hVIVO Deal Over Line

Read more
6 Jan 2020 17:29

UPDATE: Open Orphan To Relist On AIM Following hVIVO All-Share Merger

UPDATE: Open Orphan To Relist On AIM Following hVIVO All-Share Merger

Read more
6 Jan 2020 11:49

Open Orphan To Relist On AIM Following hVIVO All-Share Merger

Open Orphan To Relist On AIM Following hVIVO All-Share Merger

Read more
6 Jan 2020 10:55

Open Orphan inks three-year contract with mystery European firm

(Sharecast News) - Drug consulting services platform Open Orphan has won a new three-year contract with an unnamed German pharmaceutical company.

Read more
31 Dec 2019 09:46

Open Orphan Meets Acceptance Condition For Merger With hVIVO

Open Orphan Meets Acceptance Condition For Merger With hVIVO

Read more
31 Dec 2019 06:31

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
18 Dec 2019 12:54

Open Orphan signs deal with US biopharmaceutical firm SFA

(Sharecast News) - Europe-focussed rare and orphan drug consulting service provider Open Orphan announced the signing of a contract with SFA Therapeutics, a biopharmaceutical company based in Pennsylvania, on Wednesday.

Read more
18 Dec 2019 12:29

Open Orphan Unit To Assist SFA Therapeutics In Filing Drug Application

Open Orphan Unit To Assist SFA Therapeutics In Filing Drug Application

Read more
9 Dec 2019 14:36

Open Orphan agrees acquisition of hVIVO at 34% premium

(Sharecast News) - Open Orphan, the rare and orphan drug services company, has agreed the takeover of hVIVO by means of an all-share reverse take-over at a 33.8% premium.

Read more
9 Dec 2019 11:23

AIM-Listed Firms Open Orphan And hVIVO Set For Tie-Up

AIM-Listed Firms Open Orphan And hVIVO Set For Tie-Up

Read more
25 Nov 2019 14:57

Open Orphan Signs Five Companies For Genomic Health DataBANK Platform

Open Orphan Signs Five Companies For Genomic Health DataBANK Platform

Read more
18 Nov 2019 10:35

Open Orphan Teams With Carna For Human Clinical Pharmacology Trial

Open Orphan Teams With Carna For Human Clinical Pharmacology Trial

Read more
18 Nov 2019 09:58

Open Orphan signs pharmacology trial contract with Carna

(Sharecast News) - Rare and orphan drug consulting services provider Open Orphan announced the signing of a contract with Carna Bioscience for a first-in-human clinical pharmacology trial, it announced on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.